We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Jazz’s Xyrem Is First Drug to Face Patent Board Challenge
Jazz’s Xyrem Is First Drug to Face Patent Board Challenge
The U.S. Patent and Trademark Office’s recently established patent review board has received what appears to be its first challenge to a drug patent covering a business practice rather than a drug’s attributes.